



Advanced Research in Lung Injury and Lung Fibrosis

Guest Editors:

Dr. Chao He

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Dr. Huachun Cui

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Dr. Pulin Che

Department of Anesthesiology and Perioperative Medicine, Division of Molecular and Translational Biomedicine, University of Alabama at Birmingham, Birmingham, AL, USA

Deadline for manuscript submissions:

closed (31 March 2024)

Message from the Guest Editors

Dear Colleagues,

The persistent activation of immune cells such as neutrophils and macrophages is the hallmark of acute and chronic lung injury, leading to alveolar epithelial cell death and the impairment of gas exchange. However, immune cells also secrete growth factors critical for epithelial cell and fibroblast proliferation as well as differentiation to facilitate the repair. Dysregulated lung repair can lead to pulmonary fibrosis, a devastating disease currently without effective treatment. The most common one, idiopathic pulmonary fibrosis (IPF), has a medium survival time of 3–5 years. Thus, understanding the dynamic crosstalk between these cells could help to identify new therapeutic targets for both lung injury and pulmonary fibrosis. We invite you to submit original research articles or relevant topic reviews on lung injury and fibrosis, focusing on intercellular crosstalk and metabolism.

Dr. Chao He

Dr. Huachun Cui

Dr. Pulin Che

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)